Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis
- PMID: 8639781
Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis
Abstract
Proteolytic cleavage of von Willebrand factor (vWF) takes place in the circulating blood of healthy subjects and is increased in some patients with von Willebrand disease type 2A. The hemostatically active large vWF multimers are degraded to smaller less active forms. It has been suggested that the polypeptide subunit of vWF is cleaved at the peptide bond 842Tyr-843Met. We purified (approximately 10,000-fold) from human plasma a vWF-degrading protease, using chelating Sepharose, hydrophobic interaction chromatography, and gel filtration. The enzyme was found to be virtually absent in the platelet lysates obtained by repeated freezing and thawing. The proteolytic activity was associated with a high molecular weight protein (approximately 300 kD) as judged by gel filtration and sodium dodecyl sulfate-polyacrylamide gel electrophoresis. vWF was resistant against the protease in a neutral buffer at physiological ionic strength but became degraded at low salt concentration or in the presence of 1 mol/L urea. No degradation of human fibrinogen, bovine serum albumin, of calf skin collagen by the purified protease was noted under the same experimental conditions. Proteolytic activity showed a pH optimum at 8 to 9 and was strongly inhibited by chelating agents, whereas only slow inhibition was observed with N-ethylmaleimide. There was no inhibition by iodoacetamide, leupeptin, or serine protease inhibitors. The best peptidyl diazomethyl ketone inhibitor was Z-Phe-Phe-CHN2. Activation by divalent metal ions was found to increase in the following order: Zn2+ approximately Cu2+ approximately CD2+ approximately Ni2+ approximately Co2+ <Mn2+ <Mg2+ <Ca2+ <Sr2+ <Ba2+. The observed properties of the vWF-degrading enzyme differ from those of all other hitherto described proteases. Purified vWF was incubated with the protease, and the degraded material subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis after disulfide reduction. The size, amino acid composition, and amino terminal sequence of the reduced fragments confirmed that the peptide bond 842Tyr-843Met had been cleaved, ie, the same bond that has been proposed to be cleaved in vivo.
Similar articles
-
Are increased levels of von Willebrand factor in chronic coronary heart disease caused by decrease in von Willebrand factor cleaving protease activity? A study by an immunoassay with antibody against intact bond 842Tyr-843Met of the von Willebrand factor protein.Thromb Res. 2001 Aug 1;103(3):241-8. doi: 10.1016/s0049-3848(01)00320-6. Thromb Res. 2001. PMID: 11672586
-
Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion.Blood. 1996 May 15;87(10):4235-44. Blood. 1996. PMID: 8639782
-
Estimation of the von Willebrand factor-cleaving protease in plasma using monoclonal antibodies to vWF.Thromb Haemost. 1999 Nov;82(5):1382-5. Thromb Haemost. 1999. PMID: 10595622
-
Von Willebrand factor: molecular size and functional activity.Ann Hematol. 1996 Jun;72(6):341-8. doi: 10.1007/s002770050184. Ann Hematol. 1996. PMID: 8767102 Review.
-
Von Willebrand factor-cleaving protease and Upshaw-Schulman syndrome.Int J Hematol. 2002 Jan;75(1):25-34. doi: 10.1007/BF02981975. Int J Hematol. 2002. PMID: 11843286 Review.
Cited by
-
The Highs and Lows of ADAMTS13 Activity.J Clin Med. 2024 Aug 30;13(17):5152. doi: 10.3390/jcm13175152. J Clin Med. 2024. PMID: 39274365 Free PMC article. Review.
-
The Phenomenon of Thrombotic Microangiopathy in Cancer Patients.Int J Mol Sci. 2024 Aug 21;25(16):9055. doi: 10.3390/ijms25169055. Int J Mol Sci. 2024. PMID: 39201740 Free PMC article. Review.
-
The history of thrombotic thrombocytopenic purpura research: a narrative review.Ann Blood. 2024 Jun 30;9:16. doi: 10.21037/aob-23-46. Epub 2024 Feb 16. Ann Blood. 2024. PMID: 39049905 Free PMC article.
-
Novel mechanisms of action of emerging therapies of hereditary thrombotic thrombocytopenic purpura.Expert Rev Hematol. 2024 Jul;17(7):341-351. doi: 10.1080/17474086.2024.2356763. Epub 2024 May 20. Expert Rev Hematol. 2024. PMID: 38752747 Review.
-
Clearance of VWF by hepatic macrophages is critical for the protective effect of ADAMTS13 in sickle cell anemia mice.Blood. 2024 Mar 28;143(13):1293-1309. doi: 10.1182/blood.2023021583. Blood. 2024. PMID: 38142410
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous
